Health Care/Hospital

SD Biosensor Successfully Finishes JP Morgan Healthcare Conference

* Entering the US market in earnest by acquiring Meridian * Expanding into a direct sales system in 10 countries within the year * Launching plans, including the new product, 'STANDARD M10 FAST RT-PCR, CGMS' SEOUL, South Korea, Jan. 13, 2023 /PRNewswire/ -- SD Biosensor, Inc. (KS137310), Sou...

2023-01-13 15:11 2294

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

-  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. -  Debiopharm is developing Debio 4126, a novel 3-month ext...

2023-01-12 17:00 1666

iNtRON is finalizing the SAL200 Tech Transfer

* Including the contract transfers of the external studies planned for the successful out-licensing and commercialization of SAL200 BOSTON and SEOUL, South Korea, Jan. 11, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today...

2023-01-12 09:34 1814

Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs

YANGZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the Company's s...

2023-01-11 21:30 2985

Global Times: Connected in recognition: Foreign ambassadors signal a welcome for China's optimized, responsible COVID policy

BEIJING, Jan. 11, 2023 /PRNewswire/ -- As of January 8, China downgraded the management of COVID-19 from category A to the less serious category B infectious disease in light of the evolving epidemic. The Chinese government has optimized measures to combat the epidemic in accordance with the soci...

2023-01-11 18:24 1830

Global Times: 'Zhang Wenhong phenomenon' shows inclusiveness of China's public opinion sphere; policymaking based on science helps nation firmly hold strategic initiative of epidemic fight

BEIJING, Jan. 11, 2023 /PRNewswire/ -- On Friday, China released the 10th edition of the COVID-19 prevention and control protocol. Moreover, starting from Sunday, the country downgraded the management of COVID-19 from Class A to Class B and lifted quarantine requirements for inbound travelers. Th...

2023-01-11 17:49 1608

Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future

* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...

2023-01-11 08:01 2117

Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertinib for the treatment of advanced NSCLC with EGFR exon20ins...

2023-01-10 17:03 1915

FAPON to attend 41st Annual J.P. Morgan Healthcare Conference

SHENZHEN, China, Jan. 10, 2023 /PRNewswire/ -- FAPON, a leading life sciences company, today announces that its senior executive management will attend the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jielun ZHU, CFO & CIO of FAPON, will be making a corporate presentation o...

2023-01-10 16:37 1765

Futu partners Make-A-Wish fulfil unique wishes for four children living with critical illnesses

HONG KONG , Jan. 9, 2023 /PRNewswire/ -- People always welcome the new year full of anticipation. On entering a brand new year, we have good news of wishes coming true in the last two months of 2022, when Futu and Make-A-Wish successfully helped four "wish children" inAustralia, the United States...

2023-01-10 11:07 2634

SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships

* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...

2023-01-10 07:00 1501

SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'

SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...

2023-01-10 07:00 1688

Seoul Business Agency (SBA) Presents "Tech Hub Seoul" Vision in CES 2023 "Effectively inform the global stage about Seoul's technology and innovation"

SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -- The Seoul Metropolitan Government and Seoul Business Agency (SBA) coordinated the Seoul Pavilion in one of the world's largest technology conventions, CES 2023, hosted inLas Vegas , for four days fromThursday, January 5th to Sunday, January 8th. The...

2023-01-10 00:11 2369

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tre...

2023-01-09 23:25 1947

FlatTech LLC Receives Innovative Technology Contract from Vizient for EpiFaith(R) Syringe for safer epidurals

Contract awarded for products that bring improvement to health care industry TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith® Syringe for epidural has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-dri...

2023-01-09 21:00 1887

SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia

* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...

2023-01-09 21:00 2019

Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ap...

2023-01-09 20:00 1486

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S

BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...

2023-01-08 14:17 3192

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...

2023-01-07 17:29 3508

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...

2023-01-06 21:00 1843
1 ... 84858687888990 ... 257